Loading clinical trials...

COMPLETED

Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia

Genotype-phenotype Association Study of ENG and ACVRL1 Genes in the Inflammatory and Endothelial Response in Hereditary Hemorrhagic Telangiectasia (HHT)

NCT05550376•Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

View on ClinicalTrials.gov

Summary

The present project aims to study the inflammatory and endothelial responses involved in the differences in clinical events related to both genotypes (ENG vs. ACVRL1) in HHT. Accordingly, a cross-sectional study is proposed to evaluate the differences in circulating inflammatory and endothelial biomarkers, including interleukines, adhesion molecules, chemokines and immune regulatory molecules between both HHT groups.

Detailed Description

Background and rationale: Hereditary Hemorrhagic Telangiectasia (HHT) is a rare disease characterized by a multisystemic vascular dysplasia with autosomal dominant inheritance, mainly caused by mutations in ENG and ACVRL1 genes. Even though those mutations have been related to different clinical manifestations, the molecular mechanisms involved in each genetic variant have not been clarified. Methods: A cohort study will be carried out to compare the incidence of clinical events after a 12-months follow-up. The ability of these biomarkers to predict the clinical events will be assessed in a multivariate analysis.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age between 18 and 75 years.
•Confirmed diagnosis of HHT, according to the Curaçao criteria or genetic diagnosis.
•Clinically stable condition at the time of inclusion, defined as score \< 7 points on the Epistaxis Severity Score (ESS).
•Having signed the informed consent, after having received all the information concerning the study.

Exclusion Criteria

•Major coronary or cerebrovascular event in the 3 months prior to inclusion.
•Serious intercurrent illnesses, such as acute infections, outbreaks of autoimmune or inflammatory pathology, active cancer, or other pathologies that, at the investigator's discretion, could interfere with the conduct of the study.
•Major surgery during the 2 months prior to inclusion.
•Pharmacological treatment maintained during the 3 months prior to inclusion with NSAIDs, corticosteroids or chemotherapy.
•Toxic habits, including severe smoking, alcohol or drug abuse, which in the opinion of the investigator could interfere with the conduct of the study.
•Pregnancy or puerperium.
•Any other condition that limits compliance with the visits or procedures established in the protocol.

Locations (1)

Hospital Universitario Ramón y Cajal

Madrid, Madrid, Spain

Key Dates

Start Date

April 30, 2021

Primary Completion Date

December 31, 2023

Completion Date

December 31, 2023

Last Updated

March 17, 2025

Enrollment

ACTUAL participants

Conditions

Hereditary Hemorrhagic TelangiectasiaHHTRendu Osler Weber Disease

Interventions

Registry

OTHER

Institutional Registry of Rare Diseases

NCT06573723

Rare DiseasesAmyloidosis+24 more

View study

ENROLLING_BY_INVITATION

Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network

NCT07445347

Hereditary Hemorrhagic Telangiectasia (HHT)Pulmonary Hypertension+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia

Inclusion Criteria

Exclusion Criteria

Institutional Registry of Rare Diseases

Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network

Ultra-low-dose Chest CT for HHT

Quality of Life in Pediatric Participants With HHT

Doxycycline for Hereditary Hemorrhagic Telangiectasia

Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept